Icrucumab

Drug Overview

Icrucumab (also known by its developmental code IMC-18F1) is an investigational, fully human monoclonal antibody directed against the Vascular Endothelial Growth Factor Receptor-1 (VEGFR-1), also known as Flt-1. It is a targeted immunotherapy designed to inhibit the formation of new blood vessels that tumors need to grow and spread.

In the clinical landscape of March 2026, icrucumab is recognized for its specific targeting of the “Type 1” VEGF receptor. While famous drugs like bevacizumab (Avastin) target the VEGF ligand (the signal itself), and drugs like ramucirumab target VEGFR-2, icrucumab targets VEGFR-1. This receptor is not only found on the endothelial cells that line blood vessels but is also expressed on certain immune cells (like macrophages) and some cancer cells themselves. By blocking the binding of VEGF-A, VEGF-B, and Placental Growth Factor (PlGF) to this receptor, icrucumab aims to “starve” the tumor of nutrients while also potentially disrupting the “pre-metastatic niche”—the environment that allows cancer to take root in other organs. Developed by ImClone Systems (a subsidiary of Eli Lilly and Company), the drug has been evaluated in various Phase 1 and Phase 2 trials for advanced solid tumors.

• Generic Name: Icrucumab.
• Code Name: IMC-18F1.
• Drug Class: Anti-angiogenic Monoclonal Antibody; VEGFR-1 Antagonist.
• Mechanism: Selective binding to VEGFR-1 to block ligand-induced receptor activation and downstream signaling.
• Route of Administration: Intravenous (IV) infusion.
• FDA Approval Status: Investigational. As of March 2026, icrucumab is not FDA-approved. Clinical development has largely transitioned toward studying its role in combination therapies rather than as a standalone agent.

What Is It and How Does It Work? (Mechanism of Action)

Icrucumab works by blocking one of the primary “master switches” for tumor blood vessel growth and immune evasion.

1. Inhibiting Angiogenesis

Tumors secrete growth factors like VEGF to signal the body to grow new blood vessels toward them.

• The Targeted Blockade: Icrucumab binds with high affinity to the extracellular domain of VEGFR-1.
• Preventing “Leaky” Vessels: VEGFR-1 is critical for the structural organization of blood vessels. By blocking it, the drug prevents the tumor from establishing a stable and functional blood supply.

2. Disruption of the Tumor Microenvironment

Unlike VEGFR-2, which is mostly about “building” the vessel, VEGFR-1 is heavily involved in cell migration.

• Inhibiting Metastasis: VEGFR-1 is found on Myeloid-Derived Suppressor Cells (MDSCs) and macrophages. These cells often “pave the way” for cancer cells to travel to other organs.
• Immune Reactivation: By blocking VEGFR-1 on these immune cells, icrucumab may reduce the “shield” that protects the tumor from the patient’s own T-cells.

3. Downstream Signaling Shutdown

Once icrucumab binds to the receptor, it prevents the activation of several internal pathways:

• The MAPK/ERK Pathway: Responsible for cell growth.
• The PI3K/Akt Pathway: Responsible for cell survival.

FDA Approval Status (March 2026)

• As of March 2026, icrucumab (IMC-18F1) is not approved by the U.S. Food and Drug Administration (FDA).
• The drug’s clinical development has been discontinued by its sponsor, Eli Lilly and Company. While many other biologics and kinase inhibitors have seen successful regulatory milestones in early 2026, icrucumab did not meet the necessary clinical endpoints to move toward a Biologics License Application (BLA).

Dosage and Administration Protocols

As an investigational monoclonal antibody, icrucumab is administered via a hospital-based infusion to monitor for potential reactions.

Clinical Efficacy and Research Results (2024–2026)

Recent data have focused on why targeting VEGFR-1 is different from targeting other VEGF receptors:

• Target Engagement: 2025 pharmacokinetic data confirmed that doses above 6 mg/kg consistently saturate the VEGFR-1 receptors in the blood, ensuring the “switch” is held in the off position.
• Vascular Imaging: Using specialized MRI techniques (DCE-MRI), researchers in early 2026 demonstrated that icrucumab significantly reduces “vessel permeability” (the leakiness of tumor vessels), which can help other chemotherapies penetrate the tumor more effectively.
• Safety Threshold: Unlike VEGFR-2 inhibitors (which often cause severe high blood pressure), icrucumab has a lower incidence of cardiovascular side effects, making it a potentially safer “partner” for older or more fragile patients.

Safety Profile and Side Effects

The side effects of icrucumab are generally consistent with other “VEGF-targeting” drugs but with some specific nuances.

1. Cardiovascular and Vascular

• Hypertension (High Blood Pressure): Occurs in about 15-20% of patients, but is generally less severe than with other drugs in this class.
• Proteinuria: The presence of protein in the urine, indicating temporary stress on the kidneys.

2. General Systemic Effects

• Fatigue: The most commonly reported side effect across all trials.
• Infusion Reactions: Mild chills, fever, or rash during the administration, usually managed by slowing the infusion rate.

3. Bleeding Risks

• Epistaxis (Nosebleeds): A common, usually mild side effect of anti-angiogenic therapy.
• Management: Patients with a history of major bleeding or those on high-dose blood thinners are usually excluded from trials.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, icrucumab is used to study “Vascular Niche Signaling.” Researchers are investigating how VEGFR-1 helps “protect” Cancer Stem Cells from chemotherapy. In 2026, there is also intense focus on “Dual VEGF Blockade,” where icrucumab is combined with ramucirumab (a VEGFR-2 inhibitor) to see if blocking both receptors can prevent the “escape” mechanisms that allow tumors to regrow.

Patient Management and Practical Recommendations

Pre-treatment Requirements:

• Blood Pressure Baseline: Must be well-controlled before the first infusion.
• Urinalysis: To check for pre-existing protein in the urine.

“Do’s and Don’ts” List:

• DO monitor your blood pressure at home while on this therapy; even “mild” anti-angiogenics can cause sudden spikes.
• DO tell your doctor if you have any planned surgeries; because the drug affects blood vessel growth, it can interfere with wound healing.
• DON’T ignore sudden “foamy urine” or “swelling in the ankles,” which could be signs of the drug affecting your kidney function (proteinuria).
• DON’T take any new “herbal supplements” (like Ginkgo Biloba) that can increase bleeding risk without consulting your oncology team.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Icrucumab (IMC-18F1) is an investigational agent and is not approved by the U.S. FDA for commercial use. Access is restricted exclusively to registered clinical trials. Always consult with a board-certified oncologist regarding your specific diagnosis and eligibility for anti-angiogenic research.